Our 2022 Guide to Canada’s Pharmaceutical Intellectual Property Regime is a convenient all-in-one reference to the important legal and regulatory regimes governing pharmaceuticals in Canada.

The Guide provides a detailed review of the key regimes, including:

  • Data protection market exclusivity;
  • The Patented Medicines (Notice of Compliance) Regulations (PMNOC), linking generic market access to patent rights;
  • Certificate of Supplementary Protection (CSP) exclusivity;
  • Biologics; and
  • Drug pricing and market access.

We are honoured that the Guide includes a Foreword by our partner, The Right Honourable Brian Mulroney. During his tenure as the 18th Prime Minister of Canada, Mr. Mulroney championed a series of significant legislative reforms to improve protections for pharmaceuticals that continue to operate today. The COVID-19 pandemic has highlighted the importance of fostering investment in research, development and manufacturing by the innovative pharmaceutical industry in Canada. Norton Rose Fulbright’s pharmaceuticals and life sciences team understands the innovative pharmaceutical industry and will continue to work with innovators to defend their rights and maintain the benefits they bring to all Canadians.

We hope this Guide will assist in navigating the complex challenges of this rapidly evolving field.



Contacts

Gunars Gaikis
Gunars Gaikis
Senior Counsel
Email
gunars.gaikis@nortonrosefulbright.com
T: +1 416 202 6700
Kristin Wall
Kristin Wall
Partner, Lawyer, Trademark Agent
Email
kristin.wall@nortonrosefulbright.com
T: +1 416 216 3964
Orestes Pasparakis
Orestes Pasparakis
Partner
Email
orestes.pasparakis@nortonrosefulbright.com
T: +1 416 216 4815
Daniel Daniele
Daniel Daniele
Partner
Email
daniel.daniele@nortonrosefulbright.com
T: +1 416 216 2317
Brian R. Daley
Brian R. Daley
Partner
Email
brian.daley@nortonrosefulbright.com
T: +1 514 847 4764

Practice areas:

Recent publications

Court building's stone pillars viewed from below

Publication

ECJ confirms public tenders’ restrictions for companies from third countries with no procurement agreement with the EU

EU Member States may allow companies from countries that have not concluded an agreement guaranteeing equal and reciprocal access to public procurement (public procurement agreement) with the EU to participate in public tenders, provided there is no EU act excluding the relevant country.

Global | November 15, 2024

Antitrust and competition
Cricket ball resting on a cricket bat on green grass of cricket pitch

Publication

Time for the Heavy Roller? Or has the Budget finally levelled the playing field for UK Islamic Finance

Cricket players will tell you that whether a pitch is easy to bat on is not dictated by how much the balls bounce or turn, but rather, whether they do so consistently.

Global | November 15, 2024

Banking and finance

Publication

Ireland

On 31 October 2023, the Screening of Third Country Transactions Act 2023 (the “Act”), which establishes a new foreign direct investment ("FDI") screening regime in Ireland, was enacted.

Global | November 13, 2024

Antitrust and competition
Site search

Subscribe and stay up to date with the latest legal news, information and events . . .

Register now